[ad_1]

Rasi Bhadramani
- Akero Therapeutics (NASDAQ:AKRO) is up ~5% in after-hours trading Friday after announcing it will hold a conference call Jan. 27 to discuss topline results from a phase 2b study of efruxifermin in patients with compensated cirrhosis due to metabolic
[ad_2]